OR WAIT null SECS
December 20, 2024
The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.
December 03, 2024
Edwin Stone, Bernard Sagaert, and Khaled Yamout go behind the headlines to discuss what the ongoing measles outbreak in the UK means for pandemic preparedness and anti-vaccination trends; new mRNA approaches; and what Roche’s acquisition of Poseida means for complex cell therapies.
October 11, 2024
Evonik won the CPHI Excellence in Pharma Award in the “Sustainability” category in recognition of its plant-based squalene, PhytoSquene, used in parenteral drug delivery applications.
August 30, 2024
The approach makes use of clinical mass spectrometers that are already available in hospitals around the world.
June 20, 2024
The companies have completed the expansion and qualification phase and now enter a stand-by phase for five years.
May 25, 2024
In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.
April 24, 2024
Developing freeze-drying processes requires patience and deep product and process understanding.
April 16, 2024
The LNP success in mRNA vaccines leads to their establishment as a standard in mRNA delivery.
November 02, 2023
The new centralized hub will provide advanced testing of nucleic acids, which is expected to simplify mRNA substance testing.
October 12, 2023
The companies will co-promote GSK’s shingles vaccine, Shingrix, to healthcare professionals and points of vaccination in China.